Abstract:Assessment of minimal residual disease (MRD) is becoming a standard diagnostic tool for curable hematological malignancies such as chronic and acute myeloid leukemia. Multiple myeloma (MM) remains an incurable disease, as a major portion of patients even in complete response eventually relapse, suggesting that residual disease remains. Over the past decade, the treatment landscape of MM has radically changed with the introduction of new effective drugs and the availability of immunotherapy, including targeted antibodies and adoptive cell therapy. Therefore, conventional serological and morphological techniques have become suboptimal for the evaluation of depth of response. Recently, the International Myeloma Working Group (IMWG) introduced the definition of MRD negativity as the absence of clonal Plasma cells (PC) with a minimum sensitivity of <10 −5 either by next-generation sequencing (NGS) using the LymphoSIGHT platform (Sequenta/Adaptative) or by next-generation flow cytometry (NGF) using EuroFlow approaches as the reference methods. While the definition of the LymphoSIGHT platform (Sequenta/Adaptive) as the standard method derives from its large use and validation in clinical studies on the prognostic value of NGS-based MRD, other commercially available options exist. Recently, the LymphoTrack assay has been evaluated in MM, demonstrating a sensitivity level of 10 −5 , hence qualifying as an alternative effective tool for MRD monitoring in MM. Here, we will review state-of-the-art methods for MRD assessment by NGS. We will summarize how MRD testing supports clinical trials as a useful tool in dynamic risk-adapted therapy. Finally, we will also discuss future promise and challenges of NGS-based MRD determination for clinical decision-making. In addition, we will present our real-life single-center experience with the commercially available NGS strategy LymphoTrack-MiSeq. Even with the limitation of a limited number of patients, our results confirm the LymphoTrack-MiSeq platform as a cost-effective, readily available, and standardized workflow with a sensitivity of 10 −5 . Our real-life data also confirm that achieving MRD negativity is an important prognostic factor in MM.

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future

Multiple myeloma, immunotherapy and minimal residual disease

Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions

Modern approaches to assessment of minimal residual disease in multiple myeloma (plasma cell myeloma) cases

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

Role of minimal residual disease assessment in multiple myeloma

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy

Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis

Research Progress of Methods of Minimal Residual Disease Detection in Multiple Myeloma

Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma

Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions

Clinical Significance and Detection Techniques of Minimal Residual Disease in Multiple Myeloma——Review

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival

Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies

Minimal residual disease detection in lymphoma: methods, procedures and clinical significance

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia

Targeting Minimal Residual Disease

Measurable Residual Disease and Decision-Making in Multiple Myeloma

Plasma Cell-Free DNA Chromosomal Instability As Surrogate Biomarker of Treatment Response and Minimal Residual Diseases for Multiple Myeloma